Is argenx SE (ARGX) Among the Most Promising Biotech Stocks to Buy?

argenx SE (NASDAQ:ARGX) is one of the 8 Most Promising Biotech Stocks to Buy Now.

On May 9, argenx SE (NASDAQ:ARGX) reported that the U.S. Food and Drug Administration approved a label expansion for Vyvgart and Vyvgart Hytrulo. It extended use across all serotypes of adult generalized myasthenia gravis, including anti-AChR, anti-MuSK, anti-LRP4, and triple seronegative patients.

On May 7, argenx SE (NASDAQ:ARGX) reported first-quarter 2026 financials, posting $1.3 billion in global product net sales, up 63% year over year, while flagging a May 10, 2026, PDUFA date for seronegative gMG. CEO Karen Massey said argenx “continues to deliver meaningful impact,” citing a 17th consecutive quarter of VYVGART growth and pointing to expansion across MG populations.

Is argenx SE (ARGX) Among the Most Promising Biotech Stocks to Buy?

disease-4392163_1920

Argenx said it expects myositis topline data in the third quarter and MMN readouts in the fourth quarter of 2026 while advancing FcRn programs, including Phase 3-ready ARGX-213. Management added that it aims to treat 50,000 patients globally and secure 10 labeled signs by 2030, the company said.

argenx SE (NASDAQ:ARGX) is a global immunology company that works to improve the lives of people suffering from severe autoimmune diseases. It is operated in the United States, Japan, EMEA, and China.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.